BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 19761871)

  • 21. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review.
    Socha P; Horvath A; Vajro P; Dziechciarz P; Dhawan A; Szajewska H
    J Pediatr Gastroenterol Nutr; 2009 May; 48(5):587-96. PubMed ID: 19412008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.
    Sanyal AJ; Mofrad PS; Contos MJ; Sargeant C; Luketic VA; Sterling RK; Stravitz RT; Shiffman ML; Clore J; Mills AS
    Clin Gastroenterol Hepatol; 2004 Dec; 2(12):1107-15. PubMed ID: 15625656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents.
    Nadeau KJ; Ehlers LB; Zeitler PS; Love-Osborne K
    Pediatr Diabetes; 2009 Feb; 10(1):5-13. PubMed ID: 18721166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial.
    Anushiravani A; Haddadi N; Pourfarmanbar M; Mohammadkarimi V
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):613-617. PubMed ID: 30920975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metformin, vitamin E, and diet for patients with nonalcoholic fatty liver disease.
    Kadayifci A; Merriman RB
    Am J Gastroenterol; 2006 Jun; 101(6):1396; author reply 1396-7. PubMed ID: 16771968
    [No Abstract]   [Full Text] [Related]  

  • 26. Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease.
    Lin CH; Kohli R
    Curr Gastroenterol Rep; 2020 Aug; 22(10):52. PubMed ID: 32814993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial.
    Sofer E; Boaz M; Matas Z; Mashavi M; Shargorodsky M
    Metabolism; 2011 Sep; 60(9):1278-84. PubMed ID: 21411114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Sato K; Gosho M; Yamamoto T; Kobayashi Y; Ishii N; Ohashi T; Nakade Y; Ito K; Fukuzawa Y; Yoneda M
    Nutrition; 2015; 31(7-8):923-30. PubMed ID: 26059365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum high mobility group box 1 protein levels are not associated with either histological severity or treatment response in children and adults with nonalcoholic fatty liver disease.
    Yates KP; Deppe R; Comerford M; Masuoka H; Cummings OW; Tonascia J; Chalasani N; Vuppalanchi R;
    PLoS One; 2017; 12(11):e0185813. PubMed ID: 29095942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
    Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA;
    Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial.
    Sanyal AJ; Abdelmalek MF; Suzuki A; Cummings OW; Chojkier M;
    Gastroenterology; 2014 Aug; 147(2):377-84.e1. PubMed ID: 24818764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.
    Idilman R; Mizrak D; Corapcioglu D; Bektas M; Doganay B; Sayki M; Coban S; Erden E; Soykan I; Emral R; Uysal AR; Ozden A
    Aliment Pharmacol Ther; 2008 Jul; 28(2):200-8. PubMed ID: 18445142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose.
    Han Y; Shi JP; Ma AL; Xu Y; Ding XD; Fan JG
    Clin Drug Investig; 2014 Jan; 34(1):1-7. PubMed ID: 24081374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.
    Bril F; Biernacki DM; Kalavalapalli S; Lomonaco R; Subbarayan SK; Lai J; Tio F; Suman A; Orsak BK; Hecht J; Cusi K
    Diabetes Care; 2019 Aug; 42(8):1481-1488. PubMed ID: 31332029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of non-alcoholic steatohepatitis with Phyllanthus urinaria: a randomized trial.
    Wong VW; Wong GL; Chan AW; Chu WC; Choi PC; Chim AM; Yiu KK; Yu J; Chan FK; Chan HL
    J Gastroenterol Hepatol; 2013 Jan; 28(1):57-62. PubMed ID: 23034128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial.
    Janczyk W; Lebensztejn D; Wierzbicka-RuciƄska A; Mazur A; Neuhoff-Murawska J; Matusik P; Socha P
    J Pediatr; 2015 Jun; 166(6):1358-63.e1-3. PubMed ID: 25771388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver.
    Akcam M; Boyaci A; Pirgon O; Kaya S; Uysal S; Dundar BN
    Int J Vitam Nutr Res; 2011 Nov; 81(6):398-406. PubMed ID: 22673924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.
    Loomba R; Lutchman G; Kleiner DE; Ricks M; Feld JJ; Borg BB; Modi A; Nagabhyru P; Sumner AE; Liang TJ; Hoofnagle JH
    Aliment Pharmacol Ther; 2009 Jan; 29(2):172-82. PubMed ID: 18945255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Delta-tocotrienol Supplementation on Liver Enzymes, Inflammation, Oxidative stress and Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver Disease.
    Pervez MA; Khan DA; Ijaz A; Khan S
    Turk J Gastroenterol; 2018 Mar; 29(2):170-176. PubMed ID: 29749323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients.
    Askari F; Rashidkhani B; Hekmatdoost A
    Nutr Res; 2014 Feb; 34(2):143-8. PubMed ID: 24461315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.